title: Effects of interferon-tau on cattle persistently infected with bovine viral diarrhea virus.
abstract: In this study, the antiviral effects of bovine interferon-tau (boIFN-tau) on bovine viral diarrhea virus (BVDV) were examined in vitro and in vivo. In the in vitro experiments, the replication of cytopathic and non-cytopathic BVDV was inhibited in the bovine cells treated with boIFN-tau. The replication of BVDV was completely suppressed by boIFN-tau at a concentration higher than 10(2) U/ml. In order to examine the effect of boIFN-tau on virus propagation in cattle persistently infected (PI) with non-cytopathic BVDV, boIFN-tau was subcutaneously administered to PI cattle at 10(5) U/kg or 10(6) U/kg body weight 5 times per week for 2 weeks. No physical abnormality such as depression was observed in the cattle during the experiment. The mean BVDV titers in the serum of the PI cattle decreased slightly during the boIFN-tau administration period with the dose of 10(6) U/kg. However, the BVDV titers in the serum returned to the pre-administration level after the final boIFN-tau administration. These results suggest that boIFN-tau demonstrates an anti-BVDV effect, reducing the BVDV level in serum transiently when injected into PI cattle.
authors.affiliation: Animal Research Center, Hokkaido Research Organization, Shintoku, Hokkaido 081-0038, Japan. kohara-junko@hro.or.jp
authors.forename: Junko
authors.initials: J
authors.lastname: Kohara
authors.forename: Yumiko
authors.initials: Y
authors.lastname: Nishikura
authors.forename: Satoru
authors.initials: S
authors.lastname: Konnai
authors.forename: Motoshi
authors.initials: M
authors.lastname: Tajima
authors.forename: Misao
authors.initials: M
authors.lastname: Onuma
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001912:Bovine Virus Diarrhea-Mucosal Disease / Q000188:drug therapy / Q000821:virology*; D002417:Cattle; D001908:Diarrhea Viruses, Bovine Viral / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D005260:Female; D007370:Interferon Type I / Q000494:pharmacology* / Q000627:therapeutic use; D011257:Pregnancy Proteins / Q000494:pharmacology* / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D019562:Viral Load / Q000187:drug effects*
chemical_list: D000998:Antiviral Agents; D007370:Interferon Type I; D011257:Pregnancy Proteins; D011994:Recombinant Proteins; C020947:interferon tau